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ABSTRACT 
 
 The objective of this study was to determine the effects of calf milk replacer containing 
from 0% to 100% of the total protein from porcine plasma protein, with or without isoleucine 
balanced, on calf growth and health.  Four groups of 31 male Holstein calves were blocked by 
initial BW and plasma protein concentration and assigned to one of seven treatments.  
Treatments were as follows: A: control, all-milk protein milk replacer, B: 33% plasma protein 
addition, C: 33% plasma protein addition plus isoleucine, D: 67% plasma protein addition, E: 
67% plasma protein addition plus isoleucine, F: 100% plasma protein addition, and G: 100% 
plasma protein addition plus isoleucine. Calves were fed milk replacer only, twice daily for 5 wk.  
During wk 1, calves were fed at a rate of 10% of BW (reconstituted to 12.5% solids).  During wk 
2 to 5, calves were fed at a rate of 12% of BW (12.5% solids).  Body weight, body length, heart 
girth, withers height, hip height, and hip width were measured once weekly.  Blood was sampled 
during wk 4 and serum was analyzed for urea N, total protein, total globulins, and albumin. 
 Calf growth decreased with increasing addition of plasma protein in the diet. 
Supplementation with isoleucine lessened the negative effects of increasing plasma protein.  We 
observed no negative health effects with the addition of plasma protein in the diet, but neither did 
plasma protein improve measures of health status.  Provided that amino acid balance is 
maintained, porcine plasma protein can replace substantial amounts of whey protein in calf milk 
replacer with minimal effects on calf growth. 
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CHAPTER I 
 LITERATURE REVIEW 
 
INTRODUCTION 
 
Replacement heifers are one of the most costly sectors of dairy production. A recent 
survey from the USDA reported that mortality of pre-weaned heifers in 2006 was 7.8% (USDA, 
2007). Although this represents a decrease from 8.7% in 2001 (USDA, 2002), to most producers 
and advisers this is still too high. Increases in mortality and morbidity increase the cost to the 
replacement heifer sector. Although many factors impact mortality and morbidity, adequate 
nutrition in the first few weeks of the young calf’s life plays a large role. Giving the young calf 
the best possible start in life through adequate nutrition will pay off to the producer through 
decreased mortality and morbidity, in addition to potential decreases in age at first calving and 
increased future milk production. 
Milk replacer has long been a standard calf feed in the dairy industry. There are a wide 
variety of liquid feed sources on the market today. There is also much controversy over the best 
formulation and ingredients to use to achieve maximum growth, health, and performance from 
dairy calves while minimizing costs of production. 
Until the 1950s, most dairy calves were fed whole milk (Otterby and Linn,1981). Whole 
milk obviously is a great source of nutrition, but traditionally it has been the most expensive 
liquid diet option (Davis and Drackley, 1998). From an economic standpoint milk replacers have 
been the best choice for calf rearing. More than half of the dairy calves in the US are fed milk 
replacer for at least a portion of the pre-weaning period (Heinrichs et al., 1995). 
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PROTEIN AND AMINO ACID REQUIREMENTS 
The nutrient profile of milk replacers should resemble whole milk as closely as possible. 
However, typical conventional (limit-fed) milk replacers contain 20% CP and 18 to 20% crude 
fat on a DM basis and are fed at 8 to 10% of BW.   This contrasts with whole milk, which 
contains 25 to 26% CP and 28 to 30% fat on a solids basis.  Ad libitum feeding rates for calves 
are in the range of 18 to >20% of BW daily (Davis and Drackley, 1998). 
Proteins are an essential component of milk replacer because proteins supply amino acids 
for rapid growth and lean tissue disposition. Protein requirements are relatively low for 
maintenance and are determined mainly by the rate of growth. According to current 
recommendations, 188 g of protein are deposited for every kilogram of BW gain, which requires 
250 to 280 g of dietary CP intake (Davis and Drackley, 1998; NRC, 2001). Researchers have 
demonstrated, however, that the current NRC (2001) overestimates energy accretion and 
underestimates protein requirements (Van Amburgh and Drackley, 2005).  
Amino acid requirements must also be taken into account when considering protein 
requirements. The most recent dairy NRC (2001) does not consider individual amino acids for 
young calves. Limited research has been done on the amino acid requirements of the young calf. 
It has been generally assumed that, like swine and poultry, lysine and methionine are first and 
second limiting amino acids. This has been confirmed from a limited amount of research 
conducted by Williams and Hewitt (1979), Tzeng and Davis (1980) and Hill et al. (2008). The 
amino acid supply of the young calf, however, is much more complicated than that of young 
swine and poultry. The rumen is immature during the first few weeks of the calf’s life. During 
this time milk replacer bypasses the rumen via the reticular (esophageal) groove, allowing the 
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composition of the milk to remain relatively unchanged until it reaches the abomasum. If the 
esophageal groove is not closed properly, milk will enter the rumen where it will be fermented 
by the developing microbial population, which in turn significantly changes the composition of 
amino acids reaching the lower digestive tract. As the rumen begins to develop, the amino acid 
requirements and supply of the young calf become much more complex. Researchers have begun 
looking at feeding solely a liquid diet to study amino acid requirements; this allows researchers 
to study amino acid requirements without the interference of rumen development and variable 
quantities of amino acids supplied from microbial protein.  
Immune status of the calf also plays a role in amino acid requirements. Calves with an 
activated immune system will shuttle amino acids otherwise available for growth to the immune 
system to fight off infection.  Requirements of the immune system for amino acids have not yet 
been established. 
Recent interest has emerged in the use of the “ideal protein” concept in milk replacer 
formulation. This concept has been adopted in feed formulation in the swine and poultry 
industries. The theory behind this concept is described by the swine NRC (NRC, 1998) and 
considers that there is an optimal dietary pattern among essential amino acids that corresponds to 
the needs of the animal (NRC, 1998). Feeds are formulated using lysine as a reference set at 
100%, and then the target concentrations for each of the other essential amino acids are 
expressed as a percentage of lysine. This ensures that all amino acids are present in the correct 
ratio to one another, which will allow the most rapid and efficient growth at the lowest total 
dietary CP supply. 
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MILK PROTEINS IN MILK REPLACER 
 
Traditionally milk proteins make up the majority source of protein in milk replacers. 
Factors affecting the utilization of proteins are digestibility, amino acid balance, and the presence 
of antinutritional factors (Davis and Drackley, 1998). Milk proteins are highly digested by the 
young calf, have a desirable amino acid balance, and do not contain antinutritional factors.  
Early milk replacer formulations contained primarily dried skim milk as the main source 
of protein. Dried skim milk is highly digestible; however, the quality can be questionable 
depending on the amounts of heat used in processing (Tanan, 2005). Caseins are the main protein 
source in dried skim milk. Early in the young calf’s life chymosin activity is high. Chymosin 
coagulates casein in the abomasum, forming a clot, which modifies the rate of passage of 
proteins and the nature of proteins entering the small intestine. 
Whey protein is another milk protein source that is highly digestible. Unlike dried skim 
milk whey proteins do not clot under chymosin activity in the abomasum. It was thought early on 
that whey proteins could not be added to milk replacers in excess amounts (>30%) without 
decreasing health and performance (Roy, 1980). More recent research has observed no negative 
effects on health or performance in calves fed milk replacer with protein from whey protein 
concentrate (Lammers et al.1998; Terosky et al. 1997). Today most “all-milk protein” products 
are composed of dried whey, whey protein concentrate, and delactosed whey (Drackley, 2008). 
ALTERNATIVE PROTEINS 
Economics play a large role in the choice to feed milk replacer, as well as what 
ingredients are used in milk replacers. Milk replacer was originally as a cheaper alternative to 
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feeding whole saleable milk. The protein source is one of the most expensive components of 
milk replacer. In recent years the price of the common milk proteins (mainly whey proteins) used 
in commercial milk replacers has risen due to demand for whey in the human market. This 
change in the price has raised the question of whether feeding milk replacer is still as 
economical. The increased price for whey proteins has led the search for alternative protein 
sources. There has been much research looking at various alternative protein sources over the 
last several decades. There are a number of factors that go into finding a suitable alternative 
protein source. The protein must 1) be easily digested and the amino acids used by the calf, 
especially during the first 3 wk of life when the digestive system is immature, 2) contain an 
optimal amino acid balance, 3) be highly palatable, and 4) possess acceptable mixing qualities.  
Soy Protein 
Soy protein sources have been extensively researched as an alternative protein source in 
milk replacers. Soy proteins are widely available, cheap, and have a favorable amino acid profile 
(Davis and Drackley, 1998). Soy flours, soy protein concentrate, and soy protein isolate have 
been widely studied.  Soy flour (50% protein) is finely ground soybean meal. Soy protein 
concentrate (66% protein) is the protein portion of soybeans concentrated by the removal of 
soluble carbohydrates with hot aqueous ethanol. Soy isolate (85% protein) has the entire 
carbohydrate fraction removed and the protein precipitated.  
The biggest concern with using soy proteins in milk replacer are the anti-nutritional 
factors present and the adverse responses associated with soy protein use. Soy proteins have been 
shown to cause allergenic reactions in calves. Dawson et al. (1988) reported elevated serum 
antibody responses as well as villous atrophy in the small intestine of calves fed soy products 
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(flour and concentrate). They also saw a decrease in growth and diet digestibility, as well as an 
increase in nitrogen retention. Calves fed soy flour had greater negative than those fed soy 
concentrate. Gardner et al. (1990) reported an elevation in heart rate, increased respiratory rate, 
and allergic sensitivity to soybean products. 
Soy isolate is a more refined form of soy protein. Research comparing soy isolate and soy 
flour indicated that soy isolate has a high apparent digestibility and most importantly a lack of 
antibody synthesis (Lalles et al., 1995). Although a better source of protein than soy flour, soy 
isolate still was inferior to skim milk powder (Khorasani et al., 1989; Lalles et al., 1995). 
There are a number of studies that have looked at various chemical and physical 
treatments to increase the digestibility and reduce the antibody activity of soy proteins. Colvin 
and Ramsey (1968) found that exposing soy flour to an acid environment increased the rate of 
calf growth nearly two times over that of untreated soy flour. A follow-up study by Colvin and 
Ramsey (1969) found that calves fed  a milk replacer with soy flour treated with an alkali 
treatment grew as well as calves fed an acid treated soy, and both groups grew better than those 
fed an untreated soy.  
Drackley et al. (2006) looked at supplementing soy protein concentrate with glutamine to 
help overcome the decreased ADG and altered intestinal morphology caused by milk replacers 
containing soy protein concentrate. Results indicated that glutamine did not improve ADG or 
intestinal morphology. 
The amino acid profile of soy protein is deficient in methionine, threonine, and lysine 
relative to whole milk.  Kanjanapruthipong (1998) looked at the addition of threonine, 
methionine, and lysine to milk replacers containing soy protein. Average daily gain, N retention, 
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and ileal digestibility of DM were higher in calves fed soy protein with the addition of amino 
acids verses those fed soy proteins without the addition of amino acids. However, ADG, N 
retention, and ileal digestibility of DM in calves fed soy protein with amino acids were still 
lower than those of calves fed skim milk protein. 
Wheat Protein 
Wheat protein is another alternative protein source that has been researched extensively. 
Wheat gluten is the protein derived from the wet milling process of wheat, after separation of the 
starch (Davis and Drackley, 1998). Native wheat gluten has been found to be well digested by 
the calf, at 92 to 99% of milk values (Branco-Pardel et al., 1995; Toullec and Grognet, 1990), 
and with an amino acid profile complementary to whey proteins (Davis and Drackley, 2005). 
However, Kilshaw and Slade (1982) found similar antigenic effects with wheat gluten as they 
saw in soy protein. The addition of wheat gluten caused villus atrophy in intestinal tissue. 
Toullec and Grognet (1990) reported an increase in antibodies; however, calves did not develop 
any allergy symptoms. 
Native wheat gluten is unusually visocoelastic and insoluble (Tanan, 2005). Toullec and 
Grognet (1990) denatured the wheat protein by heating, which suppressed the viscoelasticity, but 
the product was still insoluble. As with soy protein, physical and chemical treatments of the 
wheat gluten have been researched as possible methods to increase digestibility. Toullec and 
Formal (1998) found that solubilized wheat gluten was slightly more digestible than native wheat 
gluten. Terui et al. (1996) showed that growth performance of calves fed spray-dried wheat 
gluten were the same as those fed solubilized wheat gluten or those fed soybean meal. 
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Soy and wheat protein have been shown to be adequate protein sources; however, 
additional processing is needed to overcome the antinutritional factors.  Also, amino acids may 
need to be added in high amounts to the diet, which in turn increases the cost of the product. 
Fish Protein 
Various forms of fish protein have been studied: spray-dried fish, fish meal, fish protein 
concentrate, and soluble partially hydrolyzed fish protein. Calves fed fish protein concentrate had 
poor growth performance and digestibility. Fish protein concentrate is also deficient in vitamin 
E, which increased calf morbidity and mortality (Huber, 1975). Hydrolyzing the fish protein 
concentrate yielded a product that when fed resulted in similar digestibility and growth 
performance to calves fed milk protein (Jenkins et al., 1982). Spray-dried fish protein also 
produced inferior results to milk protein and soy protein concentrate. Diets containing spray-
dried fish protein resulted in decreased ADG, increased fecal scores, increased rectal 
temperatures, and increased calf morbidity and mortality (Campos et al., 1982). Fish proteins 
have also yielded undesirable characteristics such as color, odor, and insolubility (Kolar and 
Wagner, 1991). 
Egg Protein 
There are large discrepancies when looking at performance data for egg protein as an 
alternative protein source in calf milk replacers. Research looking at liquid egg as an alternative 
protein source found that diets containing up to 10% liquid egg yielded similar results as diets 
containing only milk proteins (Touchette et al., 2003). In contrast, increasing spray-dried whole 
egg powder in milk replacers resulted in a large decrease in growth and feed efficiency (Quigley 
et al., 2002). As with many of the other sources of alternative proteins, spray-dried whole egg 
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powder is thought to contain antinutritional components. Quigley et al. (2002) looked at adding 
biotin to spray-dried whole egg powder to determine whether avidin inhibits growth; their results 
indicated no improvement with the addition of biotin.   
Potato and Rice Protein 
Research has also been conducted on use of potato and rice protein in milk replacers; 
however, neither has shown favorable results. Digestibility of potato protein has been found to be 
significantly lower than milk protein or wheat protein (Branco-Pardal et al., 1995). As rice 
protein concentrate increased in the diet, ADG and feed efficiency decreased (Hill et al., 2008). 
These two sources of protein also have poor amino acid profiles and are not economical. 
Plasma, Serum, and Red Blood Cell Protein 
The use of plasma proteins, serum proteins, and spray-dried red blood cells as an 
alternative protein source may be the most promising, not only from a nutrition standpoint but 
from a health standpoint as well. Health and nutrition go hand in hand in determining the success 
of calf rearing programs. Alternative protein sources previously studied were adequate from a 
nutrition standpoint, but few had any added health benefits; in fact, many compromised health 
when fed to young calves. For many years plasma protein, serum protein, and spray-dried red 
blood cells were not considered as potentially successful protein sources, as they were not 
economical. With the recent increase in the price of whey and potential increased supply of 
blood-derived proteins, along with the potential added health benefits, plasma proteins, serum 
proteins, and red blood cells now play an important role in the industry. All are high in protein 
and have a favorable amino acid profile, with the exception of methionine and isoleucine 
contents.   
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 Plasma or serum protein is collected from bovine or porcine blood obtained from 
slaughter facilities. Blood is collected from the animal, centrifuged, and the plasma or serum is 
collected and processed to preserve the functional characteristics of the proteins, which include 
immunoglobulins, albumin, fibrinogen, growth factors, and other biologically active 
components. Spray-dried red blood cells are a co-product of plasma protein production. 
From a nutritional standpoint, research has shown plasma proteins, serum proteins, and 
spray-dried red blood cells to be potential alternative sources of protein. Quigley and Bernard 
(1996) found no difference in BW gain, feed intake, feed efficiency, or fecal scores between milk 
replacers containing 25% of the total protein from plasma proteins compared to those containing 
all milk protein.  Morrill et al. (1995) compared diets containing 25% of the protein from porcine 
plasma, 25% from bovine porcine plasma, and an all-milk protein milk replacer. Calves fed milk 
replacers containing either bovine or porcine plasma gained more weight than those fed milk 
replacer containing only milk proteins. In a two-part study by Quigley and Drew (2000), no 
differences in intake of MR and starter, BW gain, feed efficiency, or fecal scores were observed 
in calves fed milk replacers ranging in 0% to 43% CP from spray-dried red blood cells. 
From a health standpoint, research has shown that plasma or serum proteins and spray-
dried animal plasma may decrease mortality and morbidity. Quigley and Wolfe (2003) compared 
milk replacers containing only whey protein concentrate, whey protein concentrate with 5% 
porcine plasma, and whey protein concentrate with 5% bovine plasma. Mortality and morbidity 
were lower for calves fed milk replacers containing plasma compared to those fed milk replacer 
containing 100% whey protein concentrate. Quigley et al. (2002) found a decrease in mortality, 
improved fecal scores, fewer days with scours, and decreased days with antibiotics with the 
addition of 20% of the protein from spray-dried bovine plasma.  
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Spray-dried animal plasma and spray-dried red blood cells have been researched and used 
extensively in the swine and poultry industries. Researchers have reported a reduction in local 
inflammation of the small intestine (Jiang et al. 2000) as well as the large intestine (Nofrarias et 
al. 2006) of pigs when fed spray-dried plasma. When animals were challenged with pathogenic 
bacteria such as E. coli or Salmonella, beneficial effects were even more pronounced. Bosi et al. 
(2004) fed spray-dried plasma to pigs challenged with E. coli and reported reduced inflammation 
and pro-inflammatory cytokine expression in the gut, reduced IgA secretion, and decreased 
intestinal mucosa damage. Challenge studies in calves have shown similar results. Quigley and 
Drew (2000) challenged calves with E. coli. Calves were fed milk replacers containing no 
additive, an antibiotic, or spray-dried plasma at 3.3% of DM. Calves fed either the milk replacer 
containing spray-dried plasma or the milk replacer containing the antibiotic had lower morbidity 
and mortality than calves fed the control. Arthington et al. (2002) challenged calves with 
coronavirus; calves fed MR supplemented with dry bovine serum powder had a decrease in 
respiratory rate and an increase in feed intake after challenge, suggesting that the bovine serum 
powder decreased the severity of the disease. 
Spray-dried serum has also been researched as an effective tool to increase the quality of 
colostrum. Arthington et al. (2000) found that adding spray-dried serum to poor-medium quality 
colostrum increased serum IgG concentrations in blood, thereby improving transfer of passive 
immunity. 
Spray-dried animal plasma or serum and red blood cells have been shown to not only be 
an effective protein source but to have potentially important health benefits as well. Future 
research is needed to look at the range of inclusion, amino acid profile, health benefits, and 
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mechanism behind these benefits.  In addition, research is needed on the use of these protein 
sources in accelerated feeding programs, as well as long-term effects of their use. 
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CHAPTER II 
DEFINING THE RANGE FOR PLASMA PROTEIN INCORPORATION IN MILK 
REPLACERS FOR DAIRY CALVES 
 
INTRODUCTION 
 
More than half of the dairy heifers in the United States are fed milk replacer during at 
least some of the preweaning period (USDA, 2007). Most conventional (limit-fed) diets contain 
20 to 22% protein and 20% fat. A number of different protein sources are used in milk replacer. 
Traditionally, diets are composed of milk protein sources because they are highly digestible, 
contain a nearly optimal amino acid profile, and are economical depending on the price of 
saleable milk and milk protein. Research in the last 20 yrs has been focused on finding 
alternative protein sources that perform similar to whey proteins, which have become the 
standard for all-milk protein milk replacers. Plasma proteins have emerged in the last 20 yrs as a 
potentially viable alternative protein source. Plasma proteins have been viewed as too expensive 
to incorporate into liquid diets as a substitute for milk protein. However, with the recent 
increases in the price of whey and predictions for even higher prices in the future, plasma 
proteins might become an economical choice. Plasma proteins are good sources of both CP and 
amino acids, with the exception of methionine and isoleucine.  
Unlike previous research looking solely at CP replacement, our laboratory has researched 
alternative proteins with a focus on amino acid balance and availability. My objective here was 
to determine the effects of milk replacers containing from 0% to 100% of the total replaceable 
protein from porcine plasma protein (PPP), without or with amino acids balanced, on calf health 
and growth.   
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MATERIALS AND METHODS 
Animals 
All procedures were conducted under protocol #09116 approved by the University of 
Illinois Institutional Animal Care and Use Committee. Four groups of 31 male Holstein calves, 
less than 1 wk old, were purchased from sale barns in Wisconsin or New York and transported to 
the University of Illinois Nutrition Field Lab site. Upon arrival calves were fed 4 L of electrolyte 
solution (Land O’ Lakes, Inc., Saint Paul, MN). Each calf was vaccinated with TSV-2 (Pfizer, 
Inc., New York, NY) and administered Excede (Pfizer) and MuSe (Intervet Shering Plough 
Animal Health, Union, NJ). Rectal temperatures were recorded and navels were sprayed with 
povidone iodine (Durvet, Inc., Blue Springs, MO).  Initial measurements of BW, body length, 
heart girth, withers height, hip height, and hip width were taken. A blood sample was taken via 
jugular venipuncture into a 10-mL evacuated serum separation tube (Becton Dickenson, 
Rutherford, NJ). Blood was centrifuged at 1300 × g for 15 min. Serum was divided into aliquots 
and stored in polypropylene tubes at -20⁰ C until analyzed later for total IgG. An additional 
blood sample was placed into a hematocrit tube and centrifuged at 1500 × g for 3 min. Plasma 
protein was determined using a refractometer. Ear notches were collected and placed into 
formalin to be analyzed later for presence of persistently infected bovine viral diarrhea (PI-BVD) 
virus.  
Housing 
Calves were housed in individual hutches (Calf-tel, Hampel Corp., Germantown, WI) 
placed 1.5 m apart from one another. Hutches were placed on crushed rock, covered by 
landscape cloth (DuPont) and a layer of straw. Straw was checked daily and added as needed. 
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Feeding and Management of Calves 
Calves were blocked on the day of arrival (d 0) by BW and plasma protein and then 
randomly assigned within block to one of seven treatments. All treatments (Table 1) resembled a 
commercial 20% CP and 20% fat formula with linear increases of PPP until all whey proteins 
were replaced by PPP, with the exception of the whey proteins provided as part of the spray-
dried fat in the formula.  The maximum amount of whey proteins replaced in the “100%” PPP 
formulas was approximately 88%. Treatments were formulated to contain 1.75% lysine, 0.51% 
methionine, and were isonitrogenous. Amino acid balance was formulated using the ideal protein 
concept using unpublished estimates from M E. Van Amburgh as the standard (Table 4). 
Treatments were as follows: A: control-all milk protein milk replacer; B: 33% PPP addition 
(NutrPro B, APC, Inc., Ankeny, IA); C: 33% PPP addition plus isoleucine (Ile) to equalize to 
diet A; D: 67% PPP addition; E: 67% PPP addition plus Ile to equalize diet A; F: 100% PPP 
addition; and G: 100% PPP addition plus Ile to equalize diet A. Milk replacers were 
manufactured by Milk Specialties Company (Dundee, IL). 
Calves were fed milk replacer twice daily at 0530 h and 1630 h for 5 wk.  During wk 1, 
calves were fed at a rate of 10% of BW (reconstituted to 12.5% solids). During wk 2 to5, calves 
were fed at a rate of 12% of BW (at 12.5% solids). Amounts fed were updated weekly based on 
BW. Milk replacer intake was recorded daily. Water was offered for ad libitum consumption and 
intake was recorded daily.  Starter was not offered until after the study ended after wk 5, because 
the study sought to observe the effects of amino acid balance and protein sources of the milk 
replacer only. 
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Health 
Health checks were performed daily, after the morning feeding. Fecal scores were 
assigned on a 1 to 4 scale: 1=well formed, 2=slightly loose but still holds some form, 3=loose 
without form, 4=water. Respiratory scores were assigned on a 1 to 5 scale: 1=normal, 2=heavy 
breathing, 3=mucous, 4=dry cough, 5=wet cough. Overall appearance and behavior of calves 
was also recorded. Rectal temperatures were recorded for every calf daily during wk 1, thereafter 
for those calves showing signs of illness. FluMeglumine (Phoenix Pharmaceuticals, Inc., 
Burlingame, CA) was administered to calves with a rectal temperature of 40⁰C or above. Navels 
were sprayed daily with povidone iodine (Durvet) until dry. Hydration status was assessed using 
fecal scores, skin tent test, eye appearance, and overall attitude. Electrolytes (Land O’ Lakes, 
Inc., Saint Paul, MN) were administered as needed. Animals were monitored multiple times 
daily for illness and dehydration status and treated as needed. On d 1 and 14, calves received 
Clostridium perfringens types C & D bacterin-toxoid (Pfizer, Inc.) and Clostridium perfringens 
type A toxoid (Novartis Animal Health, Inc.,). On d 3, d 11, and during wk 6, calves received 
Bovi-Shield Gold 5 (Pfizer). On d 19 and during wk 5, calves received Draxxin (Pfizer). Uniprim 
(Macleod Pharmaceuticals, Inc., Fort Collins, CO) was added to milk replacer once daily during 
d 0 through 4, and BMD soluble powder (Alpharma King Pharmaceuticals, Inc., Bristol, TN) 
was added to milk replacer once daily during d 6 through 12.  
Body Growth and Measurements 
Body weight, body length, heart girth, withers height, hip height, and hip width were 
measured upon arrival and weekly every Friday for the duration of the trial. Body weight and 
measurements were taken at 0900 h following feeding. 
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Blood Collection and Analysis 
Blood was sampled at arrival and during wk 4 at 0800 h after the morning feeding. Blood 
was obtained via jugular venipuncture into 10-mL evacuated serum separation tubes (Becton 
Dickenson, Rutherford, NJ). Blood was centrifuged at 1300 × g for 15 min. Serum was divided 
into aliquots in polypropylene tubes and stored at -20⁰ C until analyzed.  
Serum from the samples at arrival was analyzed for total IgG. Samples from wk 4 were 
analyzed for concentrations of urea N, total protein, and albumin. Total globulin was calculated 
as the difference between total protein and albumin.  All analyses were conducted at the 
University of Illinois College of Veterinary Medicine diagnostic laboratory using automated 
analysis procedures.  
Milk Replacer Sampling and Analysis 
Milk replacers were sampled daily and stored at -20⁰ C until analysis. Batch composites 
were prepared and analyzed by Dairy One (Ithaca, NY) for contents of DM, CP, soluble protein, 
crude fat, ash, Ca, P, Mg, K, Na, Fe, Zn, Cu, Mn, S, and Mb, by standard wet chemistry methods 
(www.dairyone.com/forage/default.htm). Samples were also sent to the University of Missouri 
Agricultural Experiment Station Laboratory for complete amino acid analysis by cation-
exchange chromatography coupled with post-column ninhydrin derivatization and quantification.  
The laboratory used base-catalyzed hydrolysis so that tryptophan content could be determined.   
Statistical Analysis 
Analysis of variance was conducted using the MIXED procedure in SAS (SAS Institute 
Inc., Cary, NC). Calf, block, and batch were defined as random effects, whereas treatment was a 
fixed effect. For variables with repeated measurements, a covariate (initial measurement) was 
used and data were analyzed separately by week. Initial BW, body length, heart girth, withers 
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height, hip height, and hip width were used as covariates for the respective measurements. 
Treatment comparisons were made using six preplanned, non-orthogonal contrasts: 1) linear 
effect of increasing PPP without supplemental Ile; 2) quadratic effect of increasing PPP without 
supplemental Ile; 3) linear effect of increasing PPP with supplemental Ile; 4) quadratic effect of 
increasing PPP with supplemental Ile; 5) effect of addition of supplemental Ile; and 6) interaction 
of the linear effect of increasing PPP with addition of Ile.  Significance was declared at P < 0.05 
and trends discussed when 0.05 < P < 0.10. Least square means were calculated and are 
presented with standard errors.  
RESULTS 
Nutrient Composition of Diets 
 Diet analyzed chemical composition of MR is shown in Table 2. All diets were 
formulated to contain 18.4% CP so that protein supply would be more limiting than energy 
supply to maximize the ability to detect differences in dietary protein utilization among 
treatments. The measured CP contents ranged from 20.4% for the control and 33% PPP diets to a 
low of 17.3% for the 100% PPP plus Ile diet.   
Amino acid analyses of MR on a DM basis are shown in Table 3. Treatments were 
formulated to contain 1.75% lysine. Actual analyzed lysine content was 1.56% for control and 
ranged from a high of 1.76% for 66% PPP plus Ile to a low of 1.44% for 100% PPP plus Ile. The 
amino acid compositions relative to lysine content are shown in Table 4. Methionine was 
formulated at 29% of lysine (i.e., 0.51% of dietary DM). Analyzed methionine content was 24% 
of lysine for control and relative methionine contents ranged from there to a high of 30% of 
lysine for 100% PPP Analyzed Ile content of the control diet was 73% of lysine. 
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Supplementation of Ile increased relative Ile content over the respective unsupplemented PPP 
diets but did not achieve the same value as the control because of the low lysine content of the 
control diet.   
Intakes 
 Overall and weekly mean intakes of DM, CP, ME, and lysine are shown in Table 5. 
There were no significant effects for overall DMI and ME intake of milk replacer, although the 
linear effect of increasing PPP in Ile-supplemented diets approached significance (P = 0.07). 
During wk 3, 4, and 5, there linear effect of increasing PPP in Ile-supplemented diets on DMI 
was significant, as DMI decreased with increasing PPP. 
 Differences in CP and lysine intakes reflect both small differences in DMI and 
differences in analyzed CP content among the diets. Overall mean CP intakes decreased in a 
quadratic manner as PPP increased either without or with supplemental Ile.  The addition of 
isoleucine to plasma protein negatively affected average CP intake (P = 0.0002).  The effect of 
increasing PPP without supplemental Ile on overall lysine intake was linear, although the 
quadratic effect approached significance (P = 0.09). The quadratic effect of increasing PPP with 
supplemental Ile was significant (P < 0.0001) on overall lysine intake. Diets supplemented with 
Ile had lower overall lysine intake (P=0.02), but the interaction of the linear effect of increasing 
PPP and Ile supplementation was significant, indicating that decreases in lysine intake for Ile-
supplemented diets became larger as the amount of PPP increased.  
Growth 
 Means for BW, ADG, and feed efficiency measurements are presented in Table 6. Initial 
BW did not differ among treatments. Final BW decreased linearly as PPP increased in diets 
without or with Ile supplementation. The overall ADG decreased linearly as PPP increased 
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regardless of Ile supplementation, and the quadratic effect of increasing PPP approached 
significance for both non-supplemented (P = 0.07) and Ile-supplemented (P = 0.06) diets.  On 
average, Ile supplementation resulted in a weak trend (P = 0.13) for improved gain:feed.  
 Stature measurements are presented in Table 7. Initial stature measurements did not differ 
significantly among treatments. Final body length and daily gain of body length decreased 
linearly as PPP increased regardless of Ile supplementation.  Final heart girth decreased linearly 
as PPP increased in either non-supplemented or Ile-supplemented diets.  The effect of Ile 
supplementation approached significance (P = 0.06) for final heart girth.  Average gain of heart 
girth decreased linearly in either supplemented or non-supplemented groups as PPP increased, 
although the effect tended (P = 0.08) to be quadratic in the non-supplemented diets. 
 Final withers height and hip height decreased linearly in both non-supplemented and Ile-
supplemented calves as dietary PPP increased. Daily gains of withers height decreased 
quadratically as PPP increased in non-supplemented diets, and the decrease tended (P = 0.06) to 
be quadratic for hip height.  The quadratic effects showed that decreases in height were greater at 
the higher levels of PPP inclusion.  The significant interaction of the linear effects of PPP and Ile 
supplementation showed that the decreases in height as PPP increased were larger in the absence 
of supplemental Ile.  
 Finale hip width decreased linearly as PPP increased in diets without supplemental Ile, 
but was not affected significantly in Ile-supplemented diets.  These differences in response 
resulted in a tendency (P = 0.08) for an interaction of linear effects of increasing PPP with Ile 
supplementation.  The daily gain of hip width decreased quadratically as PPP increased in diets 
without Ile supplementation but the decrease was linear in diets with supplemental Ile.  As a 
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result, the interaction of linear effects of increasing PPP with Ile supplementation approached 
significance (P = 0.06).    
Blood Metabolites  
Concentrations of urea N, total protein, albumin, and total globulins are presented in 
Table 8. The response of urea N in serum to increasing PPP was quadratic for diets 
supplemented with Ile, with the highest concentrations occurring in calves fed the 67% PPP diet 
and the lowest with the 100% diet.  The interaction of the linear effect of increasing PPP and Ile 
supplementation was significant, because urea in the non-supplemented diets did not increase as 
much for the 67% PPP diet and did not decrease for the 100% diet.   
In Ile-supplemented diets, increasing PPP resulted in a tendency (P = 0.06) for a 
quadratic increase of total protein in serum.  Addition of Ile increased the total protein 
concentration. Serum albumin concentration tended (P = 0.07) to decrease linearly as PPP 
increased in non-supplemented diets, although changes were small. Increasing PPP in Ile-
supplemented diets tended to increase total globulin concentrations in a quadratic manner, with 
largest concentrations for the 33% and 67% PPP diets. The addition of Ile increased total 
globulin concentration. 
Health 
 Measurements related to health are presented in Table 9.  The mean IgG concentrations 
on the day of arrival did not differ significantly among groups, although tendencies were present 
for quadratic effects of increasing PPP in non-supplemented diets (P = 0.06) and linear effects of 
increasing PPP in Ile-supplemented diets (P = 0.07). Because calves were blocked based on 
plasma protein determinations at arrival, these tendencies for pre-existing differences in IgG 
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occurred by chance.  The lowest mean IgG was in the control calves, so we do not believe that 
the differences among groups confounded interpretation of results. 
 There were no significant effects of diets on body temperatures, number of antibiotics 
treatments, fecal scores, days of scours, or respiratory scores. The addition of Ile resulted in 
decreased average electrolyte intakes for diets containing PPP. 
DISCUSSION 
 Previous research investigated PPP inclusion rates of < 33% of the dietary CP. The goal 
of the current trial was to determine response to inclusion levels higher than previous work. 
Quigley and Bernard (1996) observed that growth performance in calves fed milk replacer in 
which spray dried plasma provided 25% of the protein was similar to calves fed all whey 
proteins. Morrill et al. (1995) observed improved animal performance when calves were fed a 
diet providing 25% of the protein as spray dried plasma. In the current study we saw a decrease 
in BW, ADG, gain:feed, and stature measurements as the percentage of plasma protein increased 
in the diet.  Although not a preplanned comparison, post-hoc contrasts showed that calves fed the 
diets containing 33% of the protein as PPP had growth performance at least equal to calves fed 
the all-milk-protein control diet.  Therefore, our results agree with previous research for lower 
levels of PPP supplementation.   
 Plasma proteins are widely used in the swine industry to improve health of young piglets 
(van Dijk et al., 2001).  The potential for PPP to improve health in young calves also has been of 
interest.  Quigley et al. (2002) and Quigley and Wolfe (2003) observed decreased mortality and 
morbidity in calves fed low inclusion rates (5% of the diet) of spray dried animal plasma. In the 
current study we saw no treatment effects on scour scores, days of scours, antibiotic treatments, 
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body temperatures, or respiratory scores. Unexpectedly, we did observe a decrease in average 
amounts of electrolyte therapy when Ile was added to diets containing PPP.  
 There were few effects on blood metabolites related to N metabolism in this study.  As 
predicted, calves fed the diet with 100% of the protein as PPP without Ile supplementation had 
the lowest ADG, final size measurements, and gain:feed.  Despite this poor growth performance, 
however, serum protein concentrations did not differ from those of other groups.  
CONCLUSIONS 
 Previous research has indicated that plasma protein addition at 25% of the dietary protein 
was a good alternative protein source. Our findings support that conclusion.  Even replacing 
essentially all of the whey proteins in the diet with PPP and Ile supplementation resulted in 
overall ADG only 31% lower than calves fed the all-milk control diet.  Although we saw few 
health improvements with the addition of PPP, neither did we see any negative effects even at 
the highest inclusion rate, which is in marked contrast to as results with most other alternative 
protein sources. Growth rates and gain:feed were decreased at inclusion rates > 33% of the 
protein, although additional titration studies would be needed to more closely determine at what 
inclusion rate performance begins to be compromised.  
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TABLES 
 
 
 
Component A B C D E F G
Whey, 12.2% 53.82 53.41 53.38 45.32 43.46 2.56 -
WPC, 75.0% 12.94 5.82 5.67 - - - -
7/60 MR 29.74 30.43 30.44 31.07 31.09 31.54 31.57
Lec/Lard/Peg blend 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Dical Phos 0.62 0.42 0.42 0.41 0.47 1.30 1.38
Vitamin E 100,000 PRE 0.18 0.18 0.18 0.18 0.18 0.18 0.18
MR base mineral PR 0.38 0.38 0.38 0.38 0.38 0.38 0.38
MR base vitamin Plus 1.13 1.13 1.13 1.13 1.13 1.13 1.13
DL-Methionine 0.14 0.21 0.21 0.27 0.28 0.32 0.33
Dry MS Butter Flav 0.05 0.05 0.05 0.05 0.05 0.05 0.05
Limestone - 0.22 0.22 0.36 0.34 0.17 0.14
Nutr Pro B Plasma - 6.63 6.63 13.27 13.27 19.90 19.90
L-Lysine (HCL) 98.5% - 0.13 0.14 0.23 0.25 0.21 0.24
Isoleucine - - 0.15 - 0.30 - 0.41
Lactose - - - 6.34 7.82 41.27 43.31
CP, % 18.4 18.4 18.4 18.4 18.4 18.4 18.4
Crude Fat, % 20.0 20.0 20.0 20.0 20.0 20.0 20.0
Crude Fiber % 0.0 0.0 0.0 0.0 0.0 0.1 0.1
GE, Kcal/Kg 4716 4699 4698 4717 4723 4891 4900
Lactose % 45 45 45 45 46 50 50
Ca, % 1.04 1.04 1.04 1.04 1.04 1.04 1.04
P, % 0.70 0.70 0.70 0.70 0.70 0.70 0.70
Vitamin A, KIU/Lb 30.1 30.1 30.1 30.1 30.1 30.1 30.1
Vitamin D, KIU/Lb 10.5 10.5 10.5 10.5 10.5 10.5 10.5
Vitamin E, IU/Lb 200.0 200.0 200.0 200.0 200.0 200.0 200.0
Lysine 1.75 1.75 1.75 1.75 1.75 1.75 1.75
Methionine 0.51 0.51 0.51 0.51 0.51 0.51 0.51
Isoleucine 1.12 0.98 1.12 0.84 1.12 0.73 1.12
Threonine 1.22 1.16 1.15 1.12 1.10 1.14 1.12
Histidine 0.30 0.40 0.40 0.50 0.50 0.60 0.60
Leucine 1.89 1.84 1.83 1.80 1.78 1.82 1.79
Valine 1.06 1.09 1.08 1.13 1.12 1.21 1.19
Phenylalanine 0.58 0.71 0.71 0.84 0.84 1.00 0.99
Tryptophan 0.31 0.32 0.32 0.33 0.33 0.34 0.34
Arginine 0.50 0.67 0.67 0.84 0.83 1.01 1
Cystine 0.54 0.53 0.53 0.54 0.54 0.62 0.61
Tyrosine 0.52 0.61 0.60 0.69 0.68 0.79 0.78
Table 1. Ingredient and formulated chemical composition of experimental milk replacers.
Treatments1
1Treatments were A=control B=33% PPP C=33% PPP + isoleucine D=66% PPP E=66% PPP + isoleucine F=100% PPP G=100% PPP + isoleucine
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Component A B C D E F G
DM, % 96.4 96.2 96.4 96.6 96.6 97.0 97.4
CP, % of DM 20.4 20.4 19.1 20.0 20.4 18.4 17.3
Soluble Protein, % of CP 93 96 95 94 93 93 92
Crude fat, % of DM 18.2 16.2 18.8 17.0 18.7 18.6 20.3
Ash, % of DM 7.62 7.59 7.45 7.42 7.54 5.52 5.10
Ca, % of DM 0.91 1.00 0.99 1.00 0.99 1.09 0.99
P, % of DM 0.68 0.73 0.71 0.72 0.74 0.74 0.70
Mg, % of DM 0.12 0.12 0.12 0.11 0.11 0.08 0.07
K, % of DM 1.54 1.60 1.58 1.37 1.32 0.51 0.42
Na, % of DM 0.575 0.669 0.643 0.674 0.694 0.603 0.558
S, % of DM 0.30 0.32 0.31 0.32 0.33 0.32 0.29
DE, Mcal/g of DM 4.67 4.57 4.69 4.61 4.70 4.75 4.84
ME, Mcal/g of DM 4.34 4.23 4.36 4.27 4.37 4.42 4.52
Fe, ppm 110 132 122 107 119 108 100
Zn, ppm 74 89 83 83 87 87 70
Cu, ppm 9 15 7 10 11 8 6
Mn, ppm 43 50 49 52 89 51 40
Mb, ppm 0.18 0.18 <0.1 <0.1 <0.1 0.28 <0.1
Treatments1
1Treatments were A=control B=33% PPP C=33% PPP + isoleucine D=66% PPP E=66% PPP + isoleucine F=100% PPP G=100% PPP + isoleucine
Table 2. Analyzed chemical composition of experimental milk replacers.
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Amino acid A B C D E F G
Lysine 1.56 1.61 1.66 1.74 1.76 1.71 1.44
Methionine 0.37 0.40 0.40 0.48 0.43 0.52 0.39
Isoleucine 1.15 0.95 1.05 0.82 0.96 0.63 0.83
Threonine 1.12 1.13 1.08 1.10 1.07 1.01 0.97
Histidine 0.35 0.38 0.37 0.44 0.45 0.47 0.45
Leucine 1.87 1.81 1.73 1.78 1.75 1.61 1.55
Valine 1.06 1.04 1.00 1.10 1.11 1.08 1.04
Phenylalanine 0.61 0.66 0.64 0.76 0.78 0.81 0.78
Tryptophan 0.36 0.35 0.33 0.32 0.34 0.31 0.29
Arginine 0.52 0.59 0.57 0.72 0.75 0.83 0.80
Cysteine 0.39 0.43 0.44 0.50 0.51 0.53 0.52
Tyrosine 0.48 0.54 0.53 0.63 0.64 0.67 0.64
Methionine + Cysteine 0.76 0.84 0.84 0.98 0.94 1.05 0.91
Phenylalanine + Tyrosine 1.09 1.20 1.17 1.38 1.42 1.48 1.42
Taurine 0.06 0.07 0.07 0.07 0.06 0.07 0.06
Hydroxyproline 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Aspartic Acid 1.89 1.81 1.75 1.80 1.77 1.67 1.59
Serine 0.71 0.80 0.77 0.82 0.82 0.85 0.82
Glutamic Acid 2.92 2.71 2.60 2.56 2.52 2.28 2.18
Proline 1.04 0.98 0.95 0.95 0.92 0.85 0.82
Lanthionine 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Glycine 0.40 0.42 0.41 0.49 0.50 0.53 0.51
Alanine 0.87 0.85 0.82 0.85 0.84 0.80 0.77
Hydroxylysine 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Ornithine 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total 17.73 17.55 17.18 17.92 18.00 17.12 16.46
Treatments1
Table 3. Analyzed amino acid composition of experimental milk replacers.
1Treatments were A=control B=33% PPP C=33% PPP + isoleucine D=66% PPP E=66% PPP + isoleucine F=100% PPP G=100% PPP + isoleucine
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Component A B C D E F G Whole Milk2 Ideal3
Lysine 100 100 100 100 100 100 100 100 100
Methionine 24 25 24 28 25 30 27 32 29
Isoleucine 73 59 63 47 55 37 58 66 47
Threonine 72 71 65 63 61 59 67 56 62
Histidine 22 24 22 25 26 27 31 47 39
Leucine 120 113 104 102 99 94 108 126 111
Valine 68 65 61 63 63 63 72 80 69
Phenylalanine 39 41 38 44 44 47 55 62 58
Tryptophan 23 22 20 18 19 18 20 16 18
Arginine 33 37 35 42 43 48 56 47 106
Cysteine 25 27 26 29 29 31 36 12 26
Tyrosine 31 34 32 36 37 39 45 62 41
Tyrosine + Phenylalanine 70 75 70 80 81 86 99 124 99
Cysteine + Methionine 49 52 51 56 54 61 44 44 55
Treatments1
1Treatments were A=control B=33% PPP C=33% PPP + isoleucine D=66% PPP E=66% PPP + isoleucine F=100% PPP G=100% PPP + isoleucine
2From Milk Specialties Global database, courtesy S. Younker
3From M.E. Van Amburgh, unpublished results
Table 4. Amino acid profiles (% of lysine) compared with milk protein and proposed ideal amino acid profile.
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Variable A B C D E F G SE3 1 2 3 4 5 6
DM, g/d
   Week 1 539 521 529 538 515 524 524 24.9 0.63 0.82 0.090 0.23 0.44 0.63
   Week 2 631 654 660 663 627 659 646 36.0 0.28 0.48 0.94 0.81 0.35 0.63
   Week 3 681 678 678 682 642 668 661 37.4 0.55 0.61 0.037 0.36 0.094 0.75
   Week 4 715 720 713 706 684 692 683 40.5 0.17 0.55 0.042 0.94 0.30 0.95
   Week 5 760 761 751 738 727 724 716 34.1 0.082 0.69 0.045 0.96 0.54 0.96
   Overall 666 667 666 666 640 654 646 32.8 0.47 0.56 0.070 0.77 0.22 0.79
CP, g/d
   Week 1 110 106 101 108 104 96 90 4.9 <0.0001 0.020 <0.0001 0.083 0.0006 0.69
   Week 2 129 133 126 133 127 121 111 6.9 0.19 0.037 0.005 0.076 0.018 0.68
   Week 3 139 138 130 136 130 123 113 7.3 <0.0001 0.005 <0.0001 0.098 <0.0001 0.85
   Week 4 146 146 136 141 139 127 117 8.0 <0.0001 0.013 0.0001 0.045 0.002 0.94
   Week 5 155 155 144 148 147 133 123 7.6 <0.0001 0.040 <0.0001 0.061 0.016 0.87
   Overall 136 136 127 133 130 120 111 6.4 <0.0001 0.004 <0.0001 0.021 0.0002 0.89
ME, kcal/d
   Week 1 2490 2356 2449 2459 2398 2454 2506 116.9 0.80 0.100 0.87 0.058 0.39 0.60
   Week 2 2917 2956 3052 3027 2921 3083 3087 193.3 0.15 0.92 0.46 0.86 0.98 0.60
   Week 3 3144 3066 3137 3115 2992 3127 3157 176.0 0.93 0.41 0.49 0.11 0.88 0.71
   Week 4 3308 3252 3298 3224 3190 3239 3266 189.9 0.43 0.60 0.37 0.53 0.82 0.89
   Week 5 3512 3435 3476 3367 3389 3385 3422 182.3 0.21 0.57 0.31 0.67 0.63 0.99
   Overall 3074 3013 3081 3039 2981 3058 3089 154.0 0.97 0.45 0.68 0.34 0.76 0.74
Lysine, g/d
   Week 1 8.42 8.43 8.69 9.50 9.27 8.85 7.52 0.462 0.010 0.16 0.11 <0.0001 0.029 0.001
   Week 2 9.85 10.58 10.82 11.71 11.33 11.13 9.26 0.642 0.004 0.105 0.59 0.0003 0.046 0.010
   Week 3 10.63 10.97 11.12 12.06 11.61 11.32 9.47 0.683 0.018 0.103 0.081 0.0001 0.010 0.003
   Week 4 11.19 11.64 11.69 12.48 12.37 11.75 9.80 0.738 0.093 0.12 0.077 <0.0001 0.033 0.009
   Week 5 11.87 12.28 12.32 13.01 13.15 12.29 10.27 0.713 0.23 0.18 0.075 0.0001 0.078 0.016
   Overall 10.39 10.78 10.92 11.76 11.56 11.07 9.273 0.591 0.017 0.086 0.104 <0.0001 0.017 0.002
Table 5. Intakes of DM, CP, ME, and lysine from milk replacer.
Treatments1 Contrasts2
1Treatments were A=control B=33% PPP C=33% PPP + isoleucine D=66% PPP E=66% PPP + isoleucine F=100% PPP G=100% PPP + isoleucine
2Contrasts were 1=linear effect of increasing PPP without supplemental Ile 2=quadratic effect of increasing PPP without supplemental Ile 3=linear effect of increasing PPP with supplemental Ile 4= quadratic effect of increasing PPP with supplemental Ile 5=effect of addition of supplemental Ile 6=interaction of the linear effect of increasing PPP with addition of Ile
3SE=standard error of the mean
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Variable A B C D E F G SE3 1 2 3 4 5 6
BW, kg
   Initial 43.2 43.0 42.6 43.0 42.7 42.5 42.3 2.320 0.47 0.80 0.41 0.85 0.59 0.85
   Final 56.9 57.7 57.2 53.3 54.4 50.3 51.6 2.824 <0.0001 0.11 0.0004 0.20 0.51 0.44
ADG, g/d
   Week 1 474 518 524 283 318 348 356 100 0.030 0.88 0.051 0.9402 0.78 0.9882
   Week 2 194 192 162 132 68 -55 62 76 0.010 0.18 0.100 0.8538 0.8892 0.2939
   Week 3 312 397 403 266 427 133 229 52 0.003 0.039 0.39 0.007 0.045 0.3916
   Week 4 483 463 428 369 404 319 306 68 0.004 0.74 0.010 0.64 0.9057 0.8089
   Week 5 492 531 571 419 467 415 392 42 0.044 0.61 0.023 0.069 0.5268 0.4582
   Overall 392 422 419 292 338 232 269 27 <0.0001 0.074 <0.0001 0.064 0.21 0.42
Gain/DMI
   Week 1 0.88 1.02 1.01 0.51 0.63 0.68 0.72 0.171 0.049 0.92 0.13 0.874 0.67 0.8792
   Week 2 0.38 0.30 0.24 0.20 0.13 -0.17 0.07 0.147 0.002 0.25 0.060 0.7232 0.70 0.2251
   Week 3 0.45 0.58 0.58 0.40 0.65 0.19 0.33 0.080 0.004 0.031 0.50 0.004 0.0308 0.35
   Week 4 0.70 0.67 0.61 0.54 0.60 0.46 0.45 0.115 0.003 0.75 0.013 0.6507 0.9599 0.7265
   Week 5 0.66 0.69 0.75 0.55 0.63 0.56 0.54 0.056 0.064 0.80 0.046 0.095 0.4107 0.4611
   Overall 0.61 0.66 0.64 0.43 0.53 0.34 0.42 0.043 <0.0001 0.11 0.0004 0.1056 0.1249 0.2779
Treatments1 Contrasts2
2Contrasts were 1=linear effect of increasing PPP without supplemental Ile 2=quadratic effect of increasing PPP without supplemental Ile 3=linear effect of increasing PPP with supplemental Ile 4= quadratic effect of increasing PPP with supplemental Ile 5=effect of addition of supplemental Ile 6=interaction of the linear effect of increasing PPP with addition of Ile
Table 6. Calf body weight (BW), average daily gain (ADG), and gain to feed ration.
1Treatments were A=control B=33% PPP C=33% PPP + isoleucine D=66% PPP E=66% PPP + isoleucine F=100% PPP G=100% PPP + isoleucine
3SE=standard error of the mean
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Variable A B C D E F G SE3 1 2 3 4 5 6
Body length, cm
   Initial 65.3 64.6 65.1 64.3 64.3 65.0 65.6 1.30 0.55 0.13 0.89 0.11 0.31 0.95
   Final 72.1 71.5 71.8 69.9 70.2 70.1 70.6 1.61 0.001 0.45 0.009 0.55 0.43 0.87
   Overall daily gain 0.20 0.19 0.19 0.15 0.16 0.15 0.15 0.027 0.001 0.95 0.003 0.71 0.86 0.94
Heart girth, cm
   Initial 79.2 78.6 79.0 78.2 79.2 78.3 78.5 1.83 0.12 0.42 0.44 0.6208 0.1559 0.8673
   Final 86.4 86.4 86.9 83.7 85.0 82.5 83.7 1.86 <0.0001 0.37 0.0006 0.1547 0.057 0.6065
   Overall daily gain 0.21 0.22 0.23 0.15 0.17 0.12 0.15 0.015 <0.0001 0.076 0.0005 0.1746 0.2239 0.3926
Withers height, cm
   Initial 79.3 78.5 79.7 77.9 78.8 79.0 78.6 1.40 0.49 0.07 0.13 0.4812 0.206 0.100
   Final 84.4 83.9 84.2 82.5 83.7 81.9 82.4 1.35 <0.0001 0.98 0.005 0.2807 0.1332 0.90
   Overall daily gain 0.15 0.15 0.13 0.13 0.14 0.08 0.11 0.013 <0.0001 0.040 0.017 0.4455 0.4501 0.043
Hip height, cm
   Initial 82.5 82.1 82.9 81.9 82.5 82.7 82.4 1.50 0.89 0.26 0.75 0.62 0.40 0.31
   Final 87.9 87.8 87.5 86.1 87.3 85.5 86.3 1.38 <0.0001 0.67 0.045 0.5714 0.1604 0.2744
   Overall daily gain 0.15 0.16 0.13 0.11 0.14 0.08 0.11 0.016 <0.0001 0.057 0.008 0.7923 0.2673 0.006
Hip width, cm
   Initial 17.6 17.5 17.4 17.4 18.0 17.6 17.7 0.46 0.88 0.36 0.17 0.81 0.22 0.60
   Final 19.4 19.7 19.3 18.9 19.4 18.8 19.0 0.39 0.0004 0.32 0.19 0.5249 0.681 0.080
   Overall daily gain 0.05 0.06 0.05 0.04 0.04 0.04 0.04 0.013 <0.0001 0.039 0.006 0.5258 0.627 0.064
Table 7. Stature measurements.
Treatments1 Contrasts2
1Treatments were A=control B=33% PPP C=33% PPP + isoleucine D=66% PPP E=66% PPP + isoleucine F=100% PPP G=100% PPP + isoleucine
2Contrasts were 1=linear effect of increasing PPP without supplemental Ile 2=quadratic effect of increasing PPP without supplemental Ile 3=linear effect of increasing PPP with supplemental Ile 4= quadratic effect of increasing PPP with supplemental Ile 5=effect of addition of supplemental Ile 6=interaction of the linear effect of increasing PPP with addition of Ile
3SE=standard error of the mean
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